share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  09/07 05:05

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. has announced the postponement of its 2024 Annual Meeting of Stockholders, which was originally scheduled for October 2, 2024. The new date for the Annual Meeting is set for December 18, 2024, with the record date being October 25, 2024. This decision was made by the Board of Directors, who deemed the delay to be in the best interests of the stockholders. The company, which did not hold an annual meeting in 2023, has also provided a deadline for the submission of qualified stockholder proposals or director nominations. According to the Securities Exchange Act of 1934 and the company's bylaws, the cut-off for proposals or nominations to be included in the proxy statement is September 16, 2024. All submissions must adhere to the requirements of the SEC's rules and regulations, including Rule 14a-8. The report was signed by Dr. David Tapolczay, CEO of Conduit Pharmaceuticals.
Conduit Pharmaceuticals Inc. has announced the postponement of its 2024 Annual Meeting of Stockholders, which was originally scheduled for October 2, 2024. The new date for the Annual Meeting is set for December 18, 2024, with the record date being October 25, 2024. This decision was made by the Board of Directors, who deemed the delay to be in the best interests of the stockholders. The company, which did not hold an annual meeting in 2023, has also provided a deadline for the submission of qualified stockholder proposals or director nominations. According to the Securities Exchange Act of 1934 and the company's bylaws, the cut-off for proposals or nominations to be included in the proxy statement is September 16, 2024. All submissions must adhere to the requirements of the SEC's rules and regulations, including Rule 14a-8. The report was signed by Dr. David Tapolczay, CEO of Conduit Pharmaceuticals.
Conduit Pharmaceuticals公司宣布推迟其2024年股东年度会议,该会议原计划于2024年10月2日举行。年度会议的新日期已定于2024年12月18日,登记日期为2024年10月25日。这一决定是由董事会作出的,他们认为推迟对股东最有利。该公司在2023年没有召开股东年度会议,同时还规定了合格股东提案或董事提名的截止日期。根据1934年证券交易法和公司章程规定,提案或提名被列入代理人声明的截止日期为2024年9月16日。所有提交必须遵守SEC的规则和法规,包括14a-8规定。报告由Conduit Pharmaceuticals首席执行官David Tapolczay博士签署。
Conduit Pharmaceuticals公司宣布推迟其2024年股东年度会议,该会议原计划于2024年10月2日举行。年度会议的新日期已定于2024年12月18日,登记日期为2024年10月25日。这一决定是由董事会作出的,他们认为推迟对股东最有利。该公司在2023年没有召开股东年度会议,同时还规定了合格股东提案或董事提名的截止日期。根据1934年证券交易法和公司章程规定,提案或提名被列入代理人声明的截止日期为2024年9月16日。所有提交必须遵守SEC的规则和法规,包括14a-8规定。报告由Conduit Pharmaceuticals首席执行官David Tapolczay博士签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息